Search Results
Your search for early matches 10467 pages
Showing 10251 - 10300Adjuvant Bisphosphonates Improve Breast Cancer Survival, Reduce Bone Recurrence in Postmenopausal Women With Early Disease
Adjuvant use of bisphosphonates reduced the risk of bone recurrence by 34% and the risk of breast cancer death by 17% in postmenopausal women with early breast cancer in a large meta-analysis conducted by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). The potentially...
Addition of Bevacizumab Fails to Improve Invasive Disease-Free Survival vs Adjuvant Chemotherapy/Trastuzumab Alone in HER2-Positive Breast Cancer
Bevacizumab (Avastin) failed to extend invasive disease–free survival when added to trastuzumab (Herceptin)-directed adjuvant chemotherapy in patients with HER2-positive breast cancer in the phase III BETH trial. Although not specifically designed to answer this question, BETH also...
High Levels of Immune Cells in Tumors May Identify Breast Cancer Patients Most Likely to Benefit From Trastuzumab
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab (Herceptin), according to results presented today at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-05)....
Ibrutinib/Rituximab Combination Leads to High Response Rate Among Patients With CLL
Nearly all of the patients with high-risk chronic lymphocytic leukemia (CLL) in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib (Imbruvica) and the antibody rituximab (Rituxan), researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting ...
Updated Myeloma Trial Shows Lenalidomide Maintenance Post-Transplant Improves Progression-Free But Not Overall Survival
A new analysis of the multiple myeloma IFM 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival. This is possibly attributed to the shorter survival time after first disease...
Long-Term Symptoms Beyond 10 Years Experienced by Prostate Cancer Survivors
Years after receiving treatment, many patients who survive prostate cancer continue to experience treatment-related symptoms, according to the findings of a study by Darwish-Yassine et al published in the Journal of Cancer Survivorship. These findings highlight the need for improvements in survivor ...
Novel Agents IPI-145 and ABT-199 Show Encouraging Results in Phase I CLL Studies
Two novel agents—the small-molecule PI3K inhibitor IPI-145 and the Bcl-2 inhibitor ABT-199—show promising activity in chronic lymphocytic leukemia (CLL), according to two phase I studies presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstracts...
Successful Chimeric Antigen Receptor–Expressing T-Cell Treatment Reported in Advanced Lymphomas
Development of autologous genetically engineered anti-CD19 chimeric antigen receptor (CAR)-expressing T cells holds promise in the treatment of hematologic malignancies. CAR T cells are being studied in adult and pediatric acute lymphocytic leukemias and in chronic lymphocytic leukemia, and...
Hypercholesterolemia May Drive the Growth of Breast Cancer
High levels of the cholesterol metabolite 27-hydroxycholesterol seem to function like estrogen and may independently drive the growth of breast cancer, according to the findings of a preclinical study by Nelson et al published in Science. They also found a possible connection between...
Nonsignificant Survival Benefit With Postoperative Radiation Therapy for Head and Neck Cancer at Academic Center vs Other Institutions
In a study reported in JAMA Otolaryngology Head & Neck Surgery, George et al evaluated radiation treatment characteristics and outcomes among head and neck squamous cell carcinoma patients receiving adjuvant external-beam radiation therapy at an academic center vs other institutions....
Nurse Navigators Improve Patient-Reported Quality of Care in Early Cancer Care
In a study reported in the Journal of Clinical Oncology, Wagner et al assessed whether a nurse navigator intervention improved quality of life or patient experience with care in patients who recently received a diagnosis of breast, colorectal, or lung cancer. Although no differences in...
Certain Symptom Clusters After Surgery for Esophageal Cancer Predict Poor Prognosis
A new study has found that several months after surgery for esophageal cancer, different symptoms cluster together in different types of patients. In addition, patients with certain symptom clusters have an increased risk of dying from their disease. The findings by Wikman et al were published...
ASCO Endorses Cancer Care Ontario Guideline for Follow-up in Colorectal Cancer Survivors
ASCO has policy and procedures for endorsing clinical practice guidelines developed by other professional organizations. As reported in the Journal of Clinical Oncology by Meyerhardt et al of the ASCO Clinical Practice Guidelines Committee, ASCO has endorsed the Cancer Care Ontario (CCO)...
Epigenetic Modification of HAND2 May Be Associated With the Development of Endometrial Cancer
In a study reported in the journal PLoS One, Allison Jones, MD, of the Elizabeth Garrett Anderson Institute for Women’s Health, University College London, and colleagues analyzed the functional role of epigenetic factors in endometrial cancer development. They found that HAND2 methylation...
Gemtuzumab Ozogamicin Reduces Minimal Residual Disease in Children With High-Risk Acute Myeloid Leukemia
Combining gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital. The results appear in the...
New Studies Provide Insight Into Melanoma Drug Resistance Pathways and Strategy for Obtaining Durable Responses
Approximately 50% of metastatic melanomas harbor the BRAF mutation, and although most of these melanomas respond dramatically to treatment with BRAF inhibitors, such as vemurafenib (Zelboraf) and dabrafenib (Tafinlar), nearly all develop resistance to the drugs within 7 to 8 months. While previous...
Targeted Intraoperative Radiotherapy Concurrent With Lumpectomy Noninferior to External-Beam Radiotherapy in Preventing Local Breast Cancer Recurrence
In a randomized noninferiority trial (TARGIT-A) reported in The Lancet, Jayant S. Vaidya, PhD, and Michael Baum, MD, of University College London, and colleagues compared risk-adapted radiotherapy using single-dose targeted intraoperative radiotherapy vs fractionated external-beam radiotherapy in...
Additional Interim Data for Lambrolizumab Show Survival Benefit for Patients With Advanced Melanoma
Additional data for the investigational anti–PD-1 immunotherapy lambrolizumab (MK-3475) were presented yesterday at the 10th International Congress of the Society for Melanoma Research in Philadelphia. In patients with advanced melanoma, lambrolizumab demonstrated an estimated 1-year overall...
Alternate VEGF Ligands Associated With Bevacizumab Resistance in Metastatic Colorectal Cancer
Results from a University of Colorado Cancer Center study indicated that bevacizumab (Avastin) resistance in patients with colorectal cancer may be due to increases in growth factors other than the targeted VEGF-A. The study, led by Christopher Lieu, MD, and published in the journal PLoS One,...
Intraoperative Radiotherapy Inferior to External Radiotherapy in Preventing Local Recurrence in Early Breast Cancer
A single session of intraoperative radiotherapy with electrons permits delivery of a radiotherapy dose equivalent to that of conventional postoperative whole-breast irradiation. In the ELIOT trial reported in The Lancet Oncology, Umberto Veronesi, MD, of the European Institute of Oncology, and...
Prognostic Score Predicts Overall Survival in Older Patients With Hodgkin Lymphoma by Second-Line Treatment Strategy
In a study reported in the Journal of Clinical Oncology, Boris Böll, MD, of University Hospital Cologne, and colleagues analyzed second-line treatment and survival in older patients with relapsed/refractory Hodgkin lymphoma in German Hodgkin Study Group first-line studies. Use of a...
Study Explains Cyclophosphamide’s Role in Preventing Graft-vs-Host Disease
Results of a Johns Hopkins study may explain why cyclophosphamide prevents graft-vs-host disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of graft-vs-host...
Persistent Significant Neurocognitive Impairment in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
In a study reported in the Journal of Clinical Oncology, Kevin R. Krill, PhD, and colleagues from St. Jude Children’s Research Hospital assessed neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia (ALL). They found pervasive significant impairment across...
Young Breast Cancer Patients With Poorer Financial Status May Experience Delays in Seeking Care
Researchers seeking to determine why breast cancers are more deadly in young women found that although only a minority of young women experience long delays between the time they detect a breast abnormality and the time they receive a diagnosis, delays in seeking care are more common in women with...
Pegfilgrastim Prophylaxis Throughout Chemotherapy Is More Effective in Preventing Febrile Neutropenia in Breast Cancer (and More Costly)
Available data suggest that risk of febrile neutropenia is greatest during the first two cycles of chemotherapy in patients with breast cancer. In a study reported in the Journal of Clinical Oncology, Maureen J. Aarts of Maastricht University Medical Centre in the Netherlands, and colleagues...
Less-Invasive Endoscopic Therapy as Effective as Esophagectomy in Early Esophageal Cancer
Use of a minimally invasive endoscopic procedure to remove superficial, early-stage esophageal cancer is as effective as surgery that takes out and rebuilds the esophagus, according to a study by researchers at Mayo Clinic in Florida. The research, published in Clinical Gastroenterology and...
Vemurafenib Produces Rapid Responses in Hairy Cell Leukemia
Preliminary results of an ongoing clinical trial suggest that the BRAF inhibitor vemurafenib (Zelboraf)—indicated for the treatment of metastatic melanoma with BRAF V600E mutation—may have an important role in the treatment of hairy cell leukemia. The cornerstone of therapy for this...
Increased Use of Local Excision to Treat Early-Stage Rectal Cancer
Recommended treatment for most stage I rectal cancers is total mesorectal excision. However, local excision is considered an alternative for T1 tumors that are < 30% of the bowel circumference, < 3 cm in size, mobile, well to moderately differentiated, and lack lymphovascular invasion in...
Early Autologous Transplantation Improves Progression-Free Survival in Aggressive Non-Hodgkin Lymphoma
The strategy of autologous stem cell transplantation as consolidation in high-intermediate– or high-risk diffuse aggressive non-Hodgkin lymphoma (NHL) has not been specifically examined in the rituximab (Rituxan) era. In a phase III trial (Southwest Oncology Group 9704) reported in The New...
Sale of Ponatinib Suspended Due to Risk of Life-Threatening Blood Clots
The U.S. Food and Drug Administration (FDA) has asked the manufacturer of the tyrosine kinase inhibitor ponatinib (Iclusig) to suspend marketing and sales of the drug because of the risk of life-threatening blood clots and severe narrowing of blood vessels. Ariad Pharmaceuticals has agreed to...
Investigational ALK Inhibitor Shows Promise in Patients With Crizotinib-Refractory, ALK-Positive Non–Small Cell Lung Cancer
Patients with non–small cell lung cancer who have the ALK gene rearrangement usually respond to the drug crizotinib (Xalkori), with a median duration of response of approximately 10 months. In a study reported by Shirish Gadgeel, MD, of Karmanos Cancer Institute in Detroit, and colleagues at...
Computer-Aided Diagnosis Tool Might Help Distinguish Small Lung Cancer Nodules From Benign Nodules
The National Lung Screening Trial reported a 20% reduction in lung cancer mortality achieved through low-dose computed tomography (CT) screening of the at-risk population, compared to screening with chest x-ray. However, challenges with the clinical implication of CT screening for lung cancer...
Prolonged Sedentary Behavior Linked to Recurrence of Precancerous Colorectal Tumors in Men
Men who spend the most time engaged in sedentary behaviors are at greatest risk for recurrence of colorectal adenomas, benign tumors that are known precursors of colorectal cancers, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer Prevention...
African American Women Are Less Likely to Benefit From HPV Vaccines for Cervical Cancer Prevention
Vaccines currently available to prevent the two most common strains of human papillomavirus (HPV), HPV 16 and 18, responsible for about 70% of cervical cancers, may not be protective in African American women, according to a study by Cathrine Hoyo, PhD, MPH, Associate Professor in the Obstetrics...
Study Clarifies Value—and Limitations—of Patient Assistance Programs for Women With Breast Cancer
Patient assistance programs can help patients with breast cancer meet a variety of needs that might otherwise interfere with getting recommended adjuvant therapies such as radiation, chemotherapy, and hormonal treatments, according to a study published recently in the online edition of...
Combining Metformin With Chemotherapy and Radiation May Improve Outcomes in Lung Cancer Patients
Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggested new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania. The findings will be presented by...
Report of Pancreatic Atrophy in Two Patients Receiving Long-Term Sorafenib
In a letter to The New England Journal of Medicine, Ségolène Hescot, MD, of Université Paris Descartes, and colleagues reported evidence of irreversible pancreatic atrophy in two patients after long-term sorafenib treatment. Both patients received cumulative doses of sorafenib...
New Molecular Diagnostics Platform Enables Rapid Detection of BRAF V600 Mutations
A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented at the AACR-NCI-EORTC International...
Robust Activity Shown for Investigational PARP Inhibitor BMN673 in BRCA-Related Cancers
In patients with heavily pretreated advanced BRCA-related breast and ovarian cancers, the investigational poly (ADP-ribose) polymerase (PARP) inhibitor BMN673 produced an objective response rate of more than 40% and delayed disease progression by more than 6 months, according to a multicenter phase ...
Sequential Addition of Gemtuzumab Ozogamicin to Standard Chemotherapy of No Benefit in Older Patients With Newly Diagnosed AML
In a phase III trial (EORTC [European Organisation for Research and Treatment of Cancer]/GIMEMA [Gruppo Italiano Malattie Ematologiche dell’Adulto] consortium AML-17 trial) reported in the Journal of Clinical Oncology, Sergio Amadori, MD, of Tor Vergata University Hospital in Rome, and...
New Nanopharmaceutical May Be Able to Overcome Resistance to Antiangiogenic Treatment
The nanopharmaceutical CRLX101, a novel inhibitor of topoisomerase-1 and hypoxia-inducible factor (HIF)-1 alpha, may be capable of overcoming resistance of tumors to antiangiogenic agents, according to preclinical and early clinical studies that have evaluated CRLX101 in combination with...
Investigational EGFR Inhibitor May Hold Promise for Some Patients With Treatment-Resistant NSCLC
Approximately 50% of non–small cell lung cancer (NSCLC) patients who develop resistance to inhibitors of the epidermal growth factor receptor (EGFR) have acquired a second mutation, T790M, which no current EGFR inhibitors target. This may change if the AstraZeneca investigational compound...
Researchers Identify Four Genetic Variants Linked to Esophageal Cancer and Barrett’s Esophagus
An international consortium co-led by researchers at Fred Hutchinson Cancer Research Center and the QIMR Berghofer Medical Research Institute in Australia has identified four genetic variants associated with an increased risk of esophageal cancer and its precursor, Barrett’s esophagus. The...
Simple Blood Test May Diagnose Lung and Other Cancers
A simple blood test that measures serum free fatty acids and their metabolites may detect early-stage lung cancer and its recurrence, according to a study from The Cleveland Clinic presented at the ANESTHESIOLOGY™ 2013 Annual Meeting in San Francisco (Abstract A4267). The study was presented ...
Optical Metabolic Imaging Can Identify Breast Cancer Subtypes and Early Treatment Response
An optical imaging technique that measures metabolic activity in cancer cells can accurately differentiate breast cancer subtypes, and it can detect responses to treatment as early as 2 days after therapy administration, according to a study published in Cancer Research. “The process of...
RTOG 0525 Subanalysis Finds Worse Outcomes With Dose-Dense vs Standard Adjuvant Temozolomide in Glioblastoma
A phase III trial (Radiation Therapy Oncology Group [RTOG] 0525; N = 833) comparing dose-dense vs standard-dose temozolomide maintenance in newly diagnosed glioblastoma showed no differences in overall survival or progression-free survival between treatments. A substudy of the trial, reported in...
No Additional Benefit of Venlafaxine or Soy Protein vs Placebo on Hot Flashes in Men With Prostate Cancer
Hot flashes occur in approximately 80% of androgen-deprived men. In a randomized study reported in the Journal of Clinical Oncology by Mara Z. Vitolins, DrPH, MPH, RD, of Wake Forest School of Medicine, and colleagues, neither venlafaxine nor soy protein—both of which have been used to...
Gemcitabine Improves Overall Survival Following Surgery for Pancreatic Cancer
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in published in the October 9 issue of...
Substantial Proportion of Older Patients Receiving First-Line Chemotherapy Experience Functional Decline
In a study reported in Journal of Clinical Oncology, Stéphanie Hoppe, PhD, of Institut Bergonié in Bordeaux, France, and colleagues assessed functional status in older patients with cancer receiving first-line chemotherapy using the Activities of Daily Living (ADL) scale. Clinically...
Study Assesses Frequency of Allogeneic Hematopoietic Cell Transplantation in Patients With AML in First Complete Remission
In a study reported in Journal of Clinical Oncology, Raya Mawad, MD, of Fred Hutchinson Cancer Research Center, and colleagues assessed the frequency of allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (AML) in first complete remission at their institution and...
